Earum Pharmaceuticals Ltd - 542724 - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer
Accepted Resignation of Mr. Parsotambhai Kantilal Purohit due to personal reasons (Membership No. ACS 57172) as Company Secretary and Compliance Officer of the Company with effect from after closure of the business hours 26th December, 2019. Earum Pharmaceuticals Ltd - 542724 - Outcome Of Board Meeting Dated 26Th December, 2019
1. Accepted Resignation of Mr. Parsotambhai Kantilal Purohit due to personal reasons (Membership No. ACS 57172) as Company Secretary and Compliance Officer of the Company with effect from after closure of the business hours 26th December, 2019. 2. Appointment Mr. Ronakkumar Narendrabhai Lalwani (Membership No. ACS 46305) as Company Secretary and Compliance Officer of the Company with effect from after closure of the business hours of 26th December, 2019 is enclosed herewith as Annexure-I. 3. Appointment Mr. Narendrakumar Gangaramdas Patel (DIN: 07017438) as an Additional Director (Non-Executive Director) of the Company with effect from 26th December, 2019 is enclosed herewith as Annexure-II. 4. Appointment of as Secretarial Auditor for the financial year 2019-20 is not consider into this meeting. 5. Reconstitution of various Committees of the Company. The Meeting of Board of Directors commenced at 11:00 A.M. and concluded at 12:00 P.M. Earum Pharmaceuticals Ltd - 542724 - Board Meeting Intimation for Intimation Under Regulation 30 Of SEBI (LODR Regulations, 2015
Earum Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/12/2019 ,inter alia, to consider and approve 1. Resignation of Mr. Parsotambhai Kantilal Purohit due to personal reasons (Membership No. ACS 57172) as Company Secretary and Compliance Officer of the Company with effect from after closure of the business hours 26th December, 2019. 2. Appoint Mr. Ronakkumar Narendrabhai Lalwani (Membership No. ACS 46305) as Company Secretary and Compliance Officer of the Company with effect from after closure of the business hours of 26th December, 2019. 3. Appoint Mr. Narendrakumar Gangaramdas Patel (DIN: 07017438) as an Additional Director (Non-Executive Director) of the Company with effect from 26th December, 2019. 4. Appoint Secretarial Auditor for the financial year 2019-20. 5. Any other Business as may be decided by the board of directors of the Company. Request you to kindly take this on record under SEBI (LODR) Regulations, 2015. Earum Pharmaceuticals Ltd - 542724 - Discrepancy In Half Yearly Results Of September 30, 2019
This is reference to our communication dated October 14, 2019 regarding the financial results, (Standalone) for half year ended September 30, 2019. The Board had approved the unaudited financial statements of the Company for the half year ended September 30th, 2019 in the meeting held on October 14, 2019. Due to inadvertent error the cash flow statements was not attached along with the financial results of the Company. We are submitting the un-audited financial results standalone for the half year ended September 30, 2019 along with the cash flow statements. Earum Pharmaceuticals Ltd - 542724 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
With reference to the above subject matter we are submitting herewith the confirmation certificate in terms of Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 received from Bigshare Services Private Limited, Registrar and Share Transfer Agent for the quarter ended on September 30,2019. Earum Pharmaceuticals Ltd - 542724 - Statement Of Utilization Of Public Issue Proceeds And Declaration Regarding No Deviation(S)/Variation(S), From The Objects Stated In Prospectus, As Per The Requirement Of Regulation 32 Of The SEBI (Listing Obligations And Disclosure Requirements)- Regulations, 2015
Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Statement for Utilization of Public Issue Proceeds for half year ended on September 30, 2019 and declaration regarding no deviation(s)/variation(s) from the Objects stated in Prospectus. We hereby further inform that the said statement is also reviewed and approved by Audit Committee of the Board at its meeting held on October 14th, 2019 as per the requirement of Regulation 32(3) of the SEBI(Listing Obligations and Disclosure Requirement Regulations, 2015 and is also available on the website of the Company . As per Regulation 32 of SEBI (LODR) Regulations, 2015, we hereby confirm that public issue proceeds have been not fully utilized and there is no deviation/variation in actual utilization of public issue proceeds from the objects as stated in the Prospectus dated June 13th, 2019. Earum Pharmaceuticals Ltd - 542724 - Compliance Certificate In Terms Of Regulation 40(9) Of SEBI (Listing And Obligations Requirements) Regulations, 2015 For The Half Year Ended On 30Th September, 2019
Certificate under Regulation 40(9) of SEBI (Listing and Obligations Requirements) Regulations, 2015 for thehalf year ended on 30th September, 2019 issued by Bigshare Services Private Limited. Registrar and Share Transfer Agent (RTA) and Mr. HardikJoshi, Practicing Company Secretary, Ahmedabad Earum Pharmaceuticals Ltd - 542724 - Financial Results For The Half Year 30.09.2019
The Board of Directors at the meeting held today i.e. 14Th October, 2019, inter alia, transacted following'' - 1. Approved Unaudited Financial Results of the Company for the half year ended on September 30, 2019 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("Listing Regulations"). We enclose herewith: a. Unaudited Annual Financial Results (Standalone) for the Half Year ended 30th September, 2019. b. Independent Auditors'' Limited Review Report on Unaudited Half Yearly Financial Results. The Meeting of the Board of Directors of the Company commenced at 11:00 A.M. and concluded at 4:15 P.M. Submitted for your kind information and necessary records Earum Pharmaceuticals Ltd - 542724 - Outcome of Board Meeting
The Board of Directors at the meeting held today i.e. 14Th October, 2019, inter alia, transacted following'' - 1. Approved Unaudited Financial Results of the Company for the half year ended on September 30, 2019 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 ("Listing Regulations"). We enclose herewith: a. Unaudited Annual Financial Results (Standalone) for the Half Year ended 30th September, 2019. b. Independent Auditors'' Limited Review Report on Unaudited Half Yearly Financial Results. The Meeting of the Board of Directors of the Company commenced at 11:00 A.M. and concluded at 4:15 P.M. Submitted for your kind information and necessary records Earum Pharmaceuticals Ltd - 542724 - Compliance Certificate Pursuant To Regulation 7 (3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Half Year Ended As On 30Th September, 2019
We hereby,certify that all activities in relation to both physical and electronic share transfer facilities are maintained by the Company's Registrar and Share Transfer Agent, Viz., BIGSHARE SERVICES PRIVATE LIMITED, Registered office: E-3 Ansa Industrial Estatesaki Vihar Road Sakinaka Mumbai Mh 400072, Which is a SEBI approved Category-I, Registrar & Transfer Agent, registered with Securities and Exchange Board of India (SEBI Registration Number: INR000001385). Further, in compliance with the provision of Regulation 7 (3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the certificate for the half year ended 30thSeptember, 2019 i.e. for the period from 04th July, 2019 to 30th September, 2019. Kindly take the same on records and acknowledge the receipt of the same. *Company listed on BSE-SME platform as on 4th July,2019.